Physician profile
Maranda Gary
NPI 1033547658
$408.10
in general payments reported to CMS, 2019-2025
13 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $93.64 | 2025 | Zilbrysq, Fintepla |
| Pfizer INC. | $51.71 | 2025 | |
| Janssen Biotech, INC. | $38.17 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.83 | 2025 | Hyqvia |
| Sk Life Science, INC. | $28.76 | 2025 | |
| Merz Pharmaceuticals, LLC | $24.05 | 2025 | Inbrija, Xeomin |
| Neurelis, INC. | $23.44 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $22.86 | 2025 | Austedo Xr |
| Impel Pharmaceuticals LLC | $21.62 | 2025 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $20.89 | 2025 | Wainua |
| Lundbeck LLC | $19.79 | 2025 | Vyepti |
| Lilly USA, LLC | $15.85 | 2025 | Kisunla |
| Eisai INC. | $15.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maranda Gary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.